Skip to main content
Equibles

SPHERA FUNDS MANAGEMENT LTD.

Position in ACAD — Acadia Pharmaceuticals Inc

CIK 1496201 TEL AVIV, L3
Back to ACAD Full portfolio

Position in ACAD

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$9,020,310
+$3,317,254 QoQ
Shares Held
356,534
+39.2% QoQ
Ownership
0.207%
of shares outstanding
% of Portfolio
1.32%
of 13F equity value
Holder Rank
#55
of 354 holders
Holding Since
Mar 2020
10 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ACAD Over Time

Shares Held

Position Value (USD)

Derivatives in ACAD

reported options exposure · as of Mar 31, 2024
CallValue
$1,849,000
CallShares
100,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

SPHERA FUNDS MANAGEMENT LTD. holds $446,002,188 across 71 Biotechnology names. ACAD ranks #13 (2.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 MLYS
Mineralys Therapeutics, Inc.
 1,469,971 $39,659,817
2 SNDX
Syndax Pharmaceuticals Inc
 1,014,606 $22,179,287
3 RARE
Ultragenyx Pharmaceutical Inc.
 588,494 $19,649,814
4 BMRN
Biomarin Pharmaceutical Inc
 328,550 $18,799,631
5 CYTK
Cytokinetics Inc
 219,987 $18,740,692
6 BBIO
BridgeBio Pharma, Inc.
 245,346 $18,273,370
7 COGT
Cogent Biosciences, Inc.
 459,340 $17,776,458
8 INSM
INSMED Inc
 118,800 $12,666,456

All Filings in ACAD

Export CSV
11 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $9,020,310 356,534
2026-03-31 $5,703,056 256,202
2025-12-31 $5,667,915 212,202
2025-09-30 $3,177,526 148,900
2025-06-30 $3,772,593 174,900
2024-12-31 $5,294,690 288,539
2024-09-30 $3,884,049 252,539
2024-06-30 $5,322,508 327,539
2024-03-31 $2,311,250 125,000
2024-03-31 $1,849,000 100,000
2020-03-31 $6,633,250 157,000